Amalgamated Bank Buys 22,916 Shares of Gilead Sciences, Inc. $GILD

Amalgamated Bank lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 9.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 270,927 shares of the biopharmaceutical company’s stock after acquiring an additional 22,916 shares during the period. Amalgamated Bank’s holdings in Gilead Sciences were worth $30,038,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Brighton Jones LLC raised its position in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 2,450 shares in the last quarter. Bison Wealth LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter worth $215,000. Golden State Wealth Management LLC raised its position in shares of Gilead Sciences by 14.5% in the first quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company’s stock worth $97,000 after buying an additional 109 shares in the last quarter. Koshinski Asset Management Inc. raised its position in shares of Gilead Sciences by 23.8% in the first quarter. Koshinski Asset Management Inc. now owns 4,350 shares of the biopharmaceutical company’s stock worth $487,000 after buying an additional 836 shares in the last quarter. Finally, Smallwood Wealth Investment Management LLC purchased a new stake in shares of Gilead Sciences in the first quarter worth $25,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Up 0.5%

GILD opened at $118.50 on Thursday. The company has a market cap of $147.04 billion, a P/E ratio of 23.61, a P/E/G ratio of 0.81 and a beta of 0.34. The business’s 50-day moving average price is $115.51 and its 200-day moving average price is $111.43. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 12 month low of $86.08 and a 12 month high of $124.61.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company’s quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on GILD shares. UBS Group raised their price target on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research report on Friday, August 8th. Royal Bank Of Canada raised their price target on Gilead Sciences from $98.00 to $100.00 and gave the company a “sector perform” rating in a research report on Wednesday, October 8th. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Needham & Company LLC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price target on the stock in a research report on Friday, July 25th. Finally, The Goldman Sachs Group raised their price target on Gilead Sciences from $105.00 to $108.00 and gave the company a “neutral” rating in a research report on Friday, October 17th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $122.61.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total value of $1,193,900.00. Following the sale, the chief executive officer directly owned 581,203 shares of the company’s stock, valued at $69,389,826.17. This trade represents a 1.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the sale, the chief financial officer directly owned 157,055 shares in the company, valued at $18,545,054.40. The trade was a 1.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 71,500 shares of company stock valued at $8,336,040 over the last ninety days. 0.27% of the stock is owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.